14 results about "Reference drug" patented technology

A request reception unit receives structure information of a candidate drug by receiving a prediction request. A derivation unit derives a feature value of the candidate drug from the structure information. A prediction unit predicts an inclusion property of the candidate drug in a liposome from a contributing feature value of the candidate drug. A screen delivery controller presents a prediction result of the inclusion property of the candidate drug in the liposome and a known characteristic of a reference drug in a comparable manner.

The application provides a trifunctional tetravalent platinum compound of captopril-aspirin ligand and a reference drug of a bifunctional tetravalent platinum compound of captopril; and develops a nanomedicine Tf-GEVs@Pt(IV) of the aspirin-captopril trifunctional tetravalent platinum compound loaded in grapefruit extracellular vesicles (GEVs). The Tf-GEVs@Pt(IV) is prepared from the trifunctional tetravalent platinum compound as an active ingredient, the carrier grapefruit extracellular vesicles (GEVs), the carrier DSPE-PEG and the transferrin modified targeting carrier DSPE-PEG-Tf. The Tf-GEVs@Pt(IV) can release the active component trifunctional tetravalent platinum compound in vivo. In addition to causing DNA damage, the trifunctional tetravalent platinum compound as the active component of the nanomedicine can effectively regulate inflammatory, fibrotic and immunosuppressive TME. The nanomedicine has a significant anti-tumor ability and has excellent therapeutic effect on metastatic malignant tumors, and is expected to provide a new candidate drug for clinical treatment of tumors and provide a new direction for research and development of new platinum drugs and anti-metastatic malignant tumor drugs.

The present application relates to the technical field of healthcare informatics, and particularly relates to an intelligent drug clinical trial scheme generation method and system, comprising: receiving multi-source data of a candidate molecule and performing standardization processing to obtain a standardized data set; retrieving associated literature based on the standardized data set to obtain a target point evidence quality report; retrieving measured data of a reference drug of the same target point based on the standardized data set to obtain a composite prediction data structure; taking the credibility label in the target point evidence quality report and the composite prediction data structure as an explicit constraint to generate a clinical trial parameter of the candidate molecule and obtain a preliminary phase I clinical trial scheme; and performing comprehensive feasibility scoring on the phase I clinical trial scheme to output a final intelligent drug clinical trial scheme. The present application makes the clinical parameters have traceable information quality basis, and the generated trial scheme carries a confidence level classification description, which is helpful to improve the transparency and checkability of clinical development decisions.

Examples of assessing susceptibility of a target pathogen based on autofluorescence, are described. In an example, a sample containing a target pathogen and a predefined concentration of a target drug may be obtained. Thereafter, autofluorescence features based on autofluorescence exhibited by the sample in response to the sample being subjected to excitation radiation, may be determined. Once the autofluorescence features are determined, they may be analyzed based on a susceptibility-detection model to determine susceptibility of the target pathogen with respect to the target drug. In an example, the susceptibility-detection model is trained based on a training autofluorescence features correlated with reference data, in which the reference data includes information pertaining to susceptibility or resistance of a reference pathogen with respect to a reference drug.

The invention belongs to the technical field of compound synthesis, and discloses a linear extensive KRAS inhibitor as well as a preparation method and application thereof, the structural general formula of the linear extensive KRAS inhibitor is as shown in formula I. The compound has certain inhibitory activity on one or more cancer cells containing KRAS mutation; wherein the inhibitory activity of part of the compounds on Miapac-2 cells is even superior to that of a reference drug gemcitabine, and the compounds can be used for preparing active drugs for inhibiting KRAS mutation cancer cells, so that more efficient and safe candidate drugs are provided for clinically treating various KRAS mutation positive cancers such as pancreatic cancer. In addition, preparation raw materials of the compound are simple, cheap and easy to obtain, the synthesis route is short, and the compound is suitable for industrial production.

To identify the type of drug and improve the accuracy of that identification. [Solution] The computer (60) includes a feature extraction unit (64a) that extracts information from an captured image (82) indicating the reflection region of light irradiated onto the target drug, and a comparison unit (64b) that compares the information extracted by the feature extraction unit 64a with information indicating the reflection region of light irradiated onto a reference drug, and determines the type of target drug based on the result of the comparison.

The invention relates to the field of medical biology, in particular to a fermentation basal culture medium which comprises 0.04-0.2 mu M of copper ions, 1.12 mM of methionine and 0.04 mM of EDTA (Ethylene Diamine Tetraacetic Acid). The invention also discloses an application of the culture medium in reducing the C-terminal amidation of the monoclonal antibody and a method for reducing the C-terminal amidation of the monoclonal antibody. The method comprises the step of inoculating cells capable of secreting and expressing the antibody into the culture medium for fermentation culture. By using the culture medium and the method, the C-terminal amidation level of the IgG4 monoclonal antibody can be remarkably reduced under the condition of not generating negative effects on cell growth metabolism and antibody yield, other quality attributes (antibody purity, acid isomer and glycoform) are kept to be comparable with a reference drug, and the culture medium and the method are suitable for industrial large-scale production.

To provide an information processing apparatus, a method for operating the information processing apparatus, and a program for operating the information processing apparatus that can contribute to verification of the validity of prediction results regarding characteristics of candidate substances encapsulated in vesicles.SOLUTION: A request reception unit receives a prediction request and accepts structural information of a candidate drug. A derivation unit derives feature quantities of the candidate drug from the structural information. A prediction unit predicts encapsulation capability of the candidate drug into a liposome based on contribution feature quantities of the candidate drug. A screen distribution control unit presents, in a comparable manner, the prediction result of the encapsulation capability of the candidate drug into the liposome and known characteristics of a reference drug.SELECTED DRAWING: Figure 15

Copper chelators of the tetradentate monoquinoline (TDMQ) series are highly efficient against several cancer cell lines. One of these selective copper chelators, TDMQ20, is highly cytotoxic on the non-small cell lung carcinoma (A549), the cervix cancer HeLa and the hepatocarcinoma HepG2 cell cultures, with IC50 values ranging from 14 to 16 μM in vitro, lower than those obtained with the reference drug 5-fluorouracil (5-FU). TDMQ20 also exhibits a significant antiproliferative activity on HeLa cells in vitro. The mechanism of its cytotoxicity and antiproliferative activity involved intracellular production of reactive oxygen species, drastic mitochondrial damages and induction of apoptosis. The selectivity of TDMQ20 for cancer cells with respect to non-cancer human cells is higher than that of 5-FU, the reference drug. These data strongly support the selection of TDMQ20 as drug-candidate to treat several human cancers.

The invention provides an artificial intelligence expert system and method for cancer drug screening based on a cell chip. The artificial intelligence expert system and method comprises the following steps: acquiring first micro-fluidic chip experimental data, reference drug molecule data of reference drug components, and one or more reference drug component directories of the reference drug components; and performing drug feature vector analysis processing on the first micro-fluidic chip experimental data to obtain a first visual recommendation result of the cell reaction feature vector set. Obtaining one or more first cell reaction feature vector set directories of the cell reaction feature vector set; and obtaining an intelligent screening result of the cancer drugs according to the similarity between the first visual recommendation result and the reference drug molecule data and the matching condition of the one or more first cell reaction feature vector set directories and the one or more reference drug component directories. The problems that traditional screening is low in efficiency, insufficient in precision and poor in interpretability are solved, and efficient and intelligent technical support is provided for research and development of anti-cancer drugs.

Embodiments of the present application provide a molecular skeleton transition processing method, device, medium and electronic equipment. The molecular skeleton transition processing method comprises: generating an atom hidden vector corresponding to a reference drug molecule according to a connection graph structure corresponding to the reference drug molecule; performing atom occlusion processing on the atom hidden vector to obtain a skeleton hidden vector and a side chain hidden vector contained in the atom hidden vector; generating a target skeleton hidden vector having a specified transition degree with the skeleton hidden vector according to the spatial distribution of the skeleton hidden vector; and generating a transition drug molecule according to the target skeleton hidden vector and the side chain hidden vector. The technical solution of the embodiments of the present application can improve the novelty of the newly generated drug molecule.

Copper chelators of the tetradentate monoquinoline (TDMQ) series are highly efficient against several cancer cell lines. One of these selective copper chelators, TDMQ20, is highly cytotoxic on the non-small cell lung carcinoma (A549), the cervix cancer HeLa and the hepatocarcinoma HepG2 cell cultures, with IC 50 values ranging from 14 to 16 mM in vitro, lower than those obtained with the reference drug 5-fluorouracil (5-FU). TDMQ20 also exhibits a significant antiproliferative activity on HeLa cells in vitro. The mechanism of its cytotoxicity and antiproliferative activity involved intracellular production of reactive oxygen species, drastic mitochondrial damages and induction of apoptosis. The selectivity of TDMQ20 for cancer cells with respect to non-cancer human cells is higher than that of 5-FU, the reference drug. These data strongly support the selection of TDMQ20 as drug-candidate to treat several human cancers.

The invention relates to the technical field of biological medicine, in particular to application of troxerutin in preparation of a medicine for improving dyslipidemia. According to the application disclosed by the invention, in a streptozotocin-induced type 2 diabetes rat model, the intervention of troxerutin for seven weeks generates a remarkable and dose-dependent improvement effect, and the effect of troxerutin reaches a level which can be compared with or even better than that of a reference drug metformin (10 mg / kg / day). And the troxerutin is derived from a natural plant, the water-soluble characteristic of the troxerutin is beneficial to absorption and metabolism, and no obvious adverse reaction is observed in the experimental period of the invention, which indicates that the troxerutin has better safety than many synthetic drugs.

The invention relates to the technical field of medical care informatics, in particular to an intelligent drug clinical test scheme generation method and system.The method comprises the steps that multi-source data of candidate molecules is received and subjected to standardization processing, and a standardized data set is obtained; retrieving the associated literature based on the standardized data set to obtain a target evidence quality report; retrieving measured data of the same-target reference drug based on the standardized data set to obtain a composite prediction data structure; taking the target evidence quality report and the credibility label in the composite prediction data structure as explicit constraints, generating clinical test parameters of candidate molecules, and obtaining a preliminary I-stage clinical test scheme; and performing comprehensive feasibility scoring on the I-stage clinical test scheme, and outputting a final intelligent drug clinical test scheme. According to the method, the clinical parameters have traceable information quality basis, the generated test scheme carries confidence level description, and the transparency and the verifiability of clinical development decisions can be improved.